Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Return on Equity (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Return on Equity for 14 consecutive years, with 0.13% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 16.0% to 0.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.13% through Dec 2025, up 16.0% year-over-year, with the annual reading at 0.13% for FY2025, 14.0% up from the prior year.
  • Return on Equity hit 0.13% in Q4 2025 for Ligand Pharmaceuticals, up from 0.05% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.13% in Q4 2025 to a low of 0.09% in Q1 2025.
  • Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.02% in 2023.
  • Biggest five-year swings in Return on Equity: dropped -6bps in 2022 and later rose 16bps in 2025.
  • Year by year, Return on Equity stood at 0.02% in 2021, then plummeted by -69bps to 0.04% in 2022, then soared by 94bps to 0.0% in 2023, then plummeted by -1429bps to 0.04% in 2024, then skyrocketed by 440bps to 0.13% in 2025.
  • Business Quant data shows Return on Equity for LGNDZ at 0.13% in Q4 2025, 0.05% in Q3 2025, and 0.08% in Q2 2025.